©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Transforming Growth Factor Activates the Promoter of Cyclin-dependent Kinase Inhibitor p15through an Sp1 Consensus Site (*)

(Received for publication, August 16, 1995; and in revised form, September 18, 1995)

Jian-Ming Li (1) Michael A. Nichols (2)(§) Subhashini Chandrasekharan (2) Yue Xiong (2) (3)(¶) Xiao-Fan Wang (1)(**)

From the  (1)Department of Pharmacology, Duke University Medical Center, Durham, North Carolina 27708 and the (2)Curriculum in Genetics and Molecular Biology, (3)Department of Biochemistry and Biophysics, Program in Molecular Biology and Biotechnology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina 27599-3280

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Transforming growth factor beta (TGF-beta) causes growth arrest in the G(1) phase in many cell types. One probable pathway for this growth inhibition is through the TGF-beta-mediated up-regulation of the cyclin-dependent kinase (CDK) inhibitor p15, which specifically inhibits the enzymatic activities of CDK4 and CDK6. An active cyclin D-CDK4/6 complex is required for pRb phosphorylation to allow the cell cycle to progress from G(1) to S phase. To study the molecular mechanism of the p15 induction by TGF-beta, we isolated a 780-base pair promoter sequence of the human p15 gene and inserted this fragment upstream of a luciferase reporter gene. When this construct was transiently transfected into HaCaT cells, luciferase activity was induced more than 10-fold upon TGF-beta treatment, indicating that the induction of p15 expression by TGF-beta is partly exerted at the transcription level. Promoter deletion analysis revealed that the sequence from -110 to -40 relative to the transcription start site is capable of conferring the 10-fold induction by TGF-beta. Within this region there are three Sp1 consensus sites. Mutation of one of these sites, GGGGCGGAG, substantially reduced both the induction by TGF-beta and the basal promoter activity, whereas mutations in the other two Sp1 sites and the spacer sequences had little effect. In addition, gel mobility shift assay indicates that the transcription factors Sp1 and Sp3 bind to this Sp1 site. Taken together, these data suggest that a specific Sp1 consensus site is involved in the mediation of TGF-beta induction as well as the basal promoter activity of the p15 gene and that Sp1 and Sp3 transcription factors might be involved in this regulation.


INTRODUCTION

Transforming growth factor betas (TGF-betas) (^1)represent a large family of cytokines with diverse activities in the regulation of cell growth, differentiation, and morphogenesis(1, 2, 3) . TGF-beta causes growth inhibition of most epithelial, endothelial, fibroblast, neuronal, lymphoid, and hematopoietic cell types(3) . TGF-beta treatment induces growth arrest in the G(1) phase of the cell cycle, and this effect has been attributed largely to an inhibition of phosphorylation of the retinoblastoma susceptibility gene product, pRb (4) . Progression through the G(1) phase of the cell cycle requires phosphorylation of pRb by G(1) cyclin-dependent kinase (CDK) complexes, particularly the cyclin D-CDK4 and cyclin D-CDK6 complexes(5) . Phosphorylation of pRb releases transcription factors, including members of the E2F transcription factor family, required for the G(1) to S phase transition of the cell cycle(6) .

Two distinct families of CDK inhibitors, represented by p16 and p21, have been identified recently and shown to be capable of binding to and inhibiting the activities of various CDK enzymes (for a recent review, see (5) ). The p16 family of CDK inhibitors specifically interacts with two closely related CDK proteins, CDK4 and CDK6, both of which have been strongly implicated as the physiological pRb kinases. One member of this family, p15, was specifically up-regulated by TGF-beta in human keratinocyte HaCaT cells(7) . The steady-state level of p15 mRNA was induced 30-fold upon TGF-beta treatment, implicating p15 as a primary effector of the TGF-beta-mediated cell cycle arrest(7) . Previously it was shown that treatment of HaCaT cells with TGF-beta caused rapid transcriptional induction of the p21 gene (also known as cip1/ WAF1/sdi1) through a p53-independent pathway, suggesting that p21 is also involved in mediating the cell cycle arrest caused by TGF-beta(8) .

The signaling pathways downstream of the TGF-beta receptor complex that lead to the inhibition of cell cycle progression are still poorly understood. Since both CDK inhibitors, p15 and p21, are up-regulated by TGF-beta treatment, they could be coordinately regulated through a similar mechanism. In this study, we attempt to elucidate the mechanism through which TGF-beta specifically up-regulates the expression of p15 by a detailed analysis of the p15promoter sequences.


EXPERIMENTAL PROCEDURES

Isolation of p15 Genomic DNA

A human placenta genomic library cloned in FIX II (Stratagene, La Jolla, CA) was screened with the full-length human p16 cDNA(9) . Of 1.2 million phage plaques screened, eight positives were isolated. Two oligonucleotide primers, 5` primer (5` AGGATCCATGGTGATGATGGGCAGCGCCCGC 3`) and 3` primer (5` GAAGCTTGGGTAAGAAAATAAAGTCGTTG 3`), specific to p15 cDNA were designed based on the previously published MTS2 genomic sequence (10) and used in polymerase chain reaction amplification to distinguish p15 from p16. Three p15 genomic clones were obtained, and clone G8 was confirmed by DNA sequencing to correspond to the p15 gene as compared with the p15 cDNA sequence(7, 11) . A 1.2-kilobase pair DNA fragment containing a 440-bp exon 1 and 780-bp sequence upstream of 5`-cDNA was isolated from clone G8 and completely sequenced by Sanger's method(12) .

Plasmid Constructs

The HindIII/SacI, ScaI/SacI, SphI/SacI, SmaI/SacI, PvuII/SacI, and EcoRI/SacI fragments of clone G8 were inserted between the SmaI and SacI sites of the pGL2-basic luciferase reporter plasmid (Promega, Madison, WI) to generate p15P751-luc, p15P463-luc, p15P165-luc, p15P113-luc, p15P35-luc, and p15P23-luc, respectively. Linker scanning mutants of the p15P113-LS series were made by site-directed mutagenesis(13) , and mutant sequences are indicated in Fig. 3A. p15P97-luc, p15P69-luc, p15P47-luc, and p15P35-luc were constructed by inserting the HindIII/SacI fragment of p15P113-LS1, XbaI/SacI fragment of the p15P113-LS3, and HindIII/SacI fragment of the p15P113-LS4 between the SmaI and SacI sites of pGL2-basic luciferase reporter plasmid. All mutations were verified by restriction enzyme digestion and DNA sequencing.


Figure 3: Scanning mutation analysis of the p15 promoter. A, scanning mutation constructs, p15P113-LS1 through p15P113-LS6, are shown with the mutated sequences. Sequences from -113 to +5 of the wild type promoter, p15P113, are also shown and the three Sp1 consensus sites underlined. The transcription initiation site is indicated by an arrow. Fold induction by TGF-beta treatment as measured in panel B is shown for each construct. B, the scanning mutants were assayed for luciferase activities as described in the legend of Fig. 1.




Figure 1: Deletion analysis of the p15 promoter. Luciferase (Luc) constructs with progressive deletions of the p15 promoter sequences are shown. The restriction sites used in the construction of these deletion constructs are indicated. The initiator (Inr) sequence is indicated as an open box, and the transcription initiation site is indicated by an arrow. The deletion constructs were transiently transfected into HaCaT cells and the RLU measured after cells were treated with or without 100 pM human TGF-beta1. Each bar represents the mean RLU of two duplicate experiments under the same assay condition. The fold inductions by TGF-beta treatment are shown to the left of bar graph.



Gel Mobility Shift Assay

Complementary oligonucleotides from -68 to -82 on the p15 promoter were annealed and labeled with [-P]ATP by T4 polynucleotide kinase. HaCaT cells were treated with or without TGF-beta for 20 h, and the nuclear extract was prepared according to Dignam et al.(14) . 1 µg of total nuclear protein was incubated with 0.5 µg of poly(dIbulletdC) as well as the appropriate oligonucleotide competitors or antisera (as indicated in the figure legend) for 20 min on ice in a 20-µl reaction containing 20 mM Hepes (pH 7.5), 5 mM MgCl(2), 60 mM KCl, 1 mM dithiothreitol, 0.1% Triton X-100, and 6% glycerol. 0.2 ng of the end-labeled probe (2 times 10^5 cpm) were then added, and the incubation was continued for 20 min at 30 °C. The protein-DNA complexes were resolved on a 4% non-denaturing polyacrylamide gel. The gel was dried and exposed to x-ray film. Rabbit anti-human Sp1 and Sp3 antibodies were generous gifts from Dr. J. Horowitz.

Luciferase Assays

HaCaT cells were plated onto 6-well plates at a density of 100,000 cells/well. Cells were grown for 48 h and transfected with 6 µg of plasmid DNA per well with the DEAE-dextran method as described elsewhere(8) . Human TGF-beta1 was added to a concentration of 100 pM, and luciferase activity was assayed 20 h later as described(8) . For each transfected plasmid, two duplicates were assayed under the same conditions, and the mean relative light units (RLU) were used in all the figures.


RESULTS AND DISCUSSION

A 780-bp genomic DNA fragment, which contains sequences upstream of the previously reported 5`-ends of the p15 cDNA(7, 11) , was cloned from a human genomic library. The 5`-end of the p15 mRNA was mapped to the adenosine in the sequence CCCCACTCT as shown in Fig. 3A by S1 nuclease protection assay (data not shown). Thus, the cloned 780-bp DNA fragment largely contains the p15 promoter sequence. The sequence around the initiation site matches the initiator sequence as defined by Smale and Baltimore(15) . No apparent TATA sequence was found around the -25 to -30 region. Therefore, the p15 promoter may be defined as a TATA-less/initiator promoter. The p15 promoter sequences are highly GC-rich (70% G + C from -200 to -1).

To determine its inducibility by TGF-beta, the 750-bp p15 promoter sequence was inserted upstream of a luciferase reporter gene in the vector pGL2-basic (Fig. 1). When the resultant construct, p15P751-luc, was transiently transfected into HaCaT cells, a 10-15-fold induction of luciferase activity was routinely observed upon TGF-beta treatment as measured by RLU (Fig. 1). Thus, the p15 promoter is capable of being induced by TGF-beta, and the transcription activation is at least partly responsible for the accumulation of p15 mRNA upon TGF-beta treatment(7) .

To identify specific promoter elements that confer the TGF-beta induction, a series of 5` processive promoter deletion constructs were generated (Fig. 1). These deletion constructs were transiently transfected into HaCaT cells and assayed for luciferase activities in the absence or presence of TGF-beta. Fig. 1shows that deletions up to the position of -110 relative to the initiation site did not change the fold of induction by TGF-beta although the overall promoter activities in the presence of TGF-beta dropped about 3-fold. Deleting sequences from -110 to -30, however, abolished TGF-beta induction (Fig. 1), indicating that a TGF-beta-responsive element is located in this region.

There are three potential Sp1 binding sites within the -110 to -30 sequences upstream of the transcription initiation site of the p15 gene. Previously, a GC-rich sequence (GCCTCC) capable of binding to Sp1 and Sp3 was shown to be responsible for the induction of p21 gene by TGF-beta treatment(30) . Interestingly, this sequence is identical to the first Sp1 consensus site in the -110 to -30 fragment of the p15 promoter. To test the possibility that this sequence, or the other two Sp1 consensus sites, may be involved in the mediation of p15 promoter induction by TGF-beta, we generated more 5` promoter deletion constructs to delete either one (p15P97-luc), two (p15P69-luc), or all three Sp1 consensus sites (p15P47-luc) and assayed for their luciferase activities in the absence or presence of TGF-beta (Fig. 2). Fig. 2shows that deletion of the first Sp1 consensus site had little effect on either the induction fold by TGF-beta or the basal promoter activity of the p15 luciferase construct, whereas deletion up to the second Sp1 consensus site reduced TGF-beta induction dramatically from 19-fold of the wild type promoter to 2.8-fold. Deletion of all three Sp1 consensus sites reduced TGF-beta induction only slightly further to 1.5-fold near the background level. These data suggest that the second Sp1 consensus site is the most critical sequence for either the induction by TGF-beta or the basal promoter activity of the human p15 promoter.


Figure 2: Deletion analysis of the Sp1 consensus sites on the p15 promoter. p15P113-luc, which contains three Sp1 consensus sites and is fully inducible by TGF-beta, is shown. Luciferase (Luc) constructs with one (p15P97), two (p15P69), and three (p15P47) Sp1 consensus sites deleted are also shown. These constructs were transiently transfected into HaCaT cells and the luciferase activity assayed as described in the legend of Fig. 1. Fold induction by TGF-beta is indicated. Inr, initiator.



To confirm the importance of the second Sp1 consensus site in conferring the transcription inducibility of the p15 promoter by TGF-beta, a series of scanning mutation constructs were made in the promoter context of p15P113, which contains 113 base pairs upstream of the transcription initiation site and is fully capable of being induced by TGF-beta (Fig. 3A). The scanning constructs were transiently transfected into HaCaT cells and assayed for their luciferase activities in the absence or presence of TGF-beta1. With the exception of p15P113-LS3, all mutants did not change significantly the fold of induction upon TGF-beta treatment or the basal transcription activity (Fig. 3B). Mutant p15P113-LS3, which contains a mutation in the second Sp1 site within the -110 to -30 region, decreased the fold of induction from 12-fold of the wild type promoter to 4-fold (Fig. 3B). In addition, the basal promoter activity of p15P113-LS3 was also reduced significantly, approaching the background level (Fig. 3B). Together with the promoter deletion analysis, these data suggest that a specific Sp1 consensus site is important for the mediation of TGF-beta induction of the p15 gene as well as its basal promoter activity.

To identify protein factors interacting with the second Sp1 site, we used DNA sequences from -68 to -82 on the p15 promoter covering the second Sp1 site in the gel mobility shift assay. As shown in Fig. 4, lane 2, three distinctive protein complexes (I, II, and III) were observed when this probe was incubated with nuclear extract prepared from HaCaT cells. All three complexes are specific to the probe since they were readily competed by an excess of cold homologous competitor (Fig. 4, lanes 9 and 10) but were resistant to the competition of nonspecific oligonucleotides (Fig. 4, lanes 7 and 8). Complex I was abolished when antibody against the human Sp1 transcription factor was included in the binding reaction and therefore represents the complex formed between Sp1 and the second Sp1 site on the p15 promoter (Fig. 4, lane 4). Similarly, complexes II and III represent the complexes formed between Sp3 and the second Sp1 site on the p15 promoter since both complexes were abolished when the binding reaction includes antibody against the transcription factor Sp3 (Fig. 4, lane 6). Together with the promoter mutation analysis, these data show that the second Sp1 site within the -110 to -30 region on the p15 promoter, which is capable of conferring the TGF-beta inducibility of the p15 promoter, binds to the transcription factors Sp1 and Sp3.


Figure 4: Factors binding to the second Sp1 site on the p15 promoter. Complementary oligonucleotides covering the second Sp1 site on the p15 promoter were labeled with [-P]ATP and used in the gel mobility shift assay. Three protein-DNA complexes (I, II, and III), as indicated by arrows, were observed when the probe was incubated with 1 µg of nuclear protein (lane 2). In lanes 3 and 4, preimmune sera or antibody against human Sp1 were included in the binding reaction, respectively. In lanes 5 and 6, preimmune sera or antibody against human Sp3 were included in the binding reaction. In lanes 7 and 8, a 50- or 250-fold excess of nonspecific oligonucleotides was included in the binding reaction. In lanes 9 and 10, a 50- or 250-fold excess of the homologous oligonucleotides was included in the binding reaction. Lane 1 is probe alone.



Sp1 consensus sites are present in numerous gene promoters including many housekeeping genes and cellular proto-oncogenes(16, 17, 18) . The well characterized transcription factor Sp1 binds to its cognate binding site and activates transcription presumably through its interaction with the TBP-associated factor 110 (TAF110) (19) . Recent studies suggest that Sp1 and a member of the Sp1 family, Sp3, are involved in the regulation of many growth-related cellular genes, including c-fos, c-myc, TGF-beta1, and TGF-beta3 genes, through a cis-acting element termed the pRb control element(16, 20, 21, 22) . A model has been proposed to postulate that the functional interaction between pRb and Sp1 in vivo results in the ``superactivation'' of Sp1-mediated transcription(16) . Here we show that a specific Sp1 consensus site is involved in the mediation of TGF-beta induction of the p15 gene and that the Sp1 and Sp3 proteins could bind to this specific Sp1 site. The same site is also responsible for the basal promoter activity. Evidence is accumulating that basal transcription machinery is also capable of being regulated in cells, presumably through the action of TBP-associated factors (TAFs). For example, p53 transcription activation is mediated by TAF40 and TAF60 (23) and the presence of TAF150 and TAF250 stabilized the preinitiation complex assembled on an initiator-containing promoter while it destabilized the complex on an initiator-less promoter(24) . A temperature-sensitive mutation in TAF250 has been shown to cause cell cycle arrest(25, 26) . It is possible that some TAFs could relay the cues received from growth signals and affect the transcription preinitiation complex assembled on certain growth-related genes.

A GC-rich sequence in the p21 promoter capable of binding to the Sp1 and Sp3 proteins was shown to be responsible for the induction of the p21 gene by TGF-beta in HaCaT cells(30) . Interestingly, this GC-rich sequence, termed TRE for TGF-beta-responsive element, was capable of conferring TGF-beta inducibility when inserted into an exogenous promoter(30) . Based on these studies, it is conceivable that the same GC-box binding factor(s) may be involved in the coordinate regulation of both p15 and p21 genes. Several proteins capable of binding to those GC-rich sequences including the Sp1 consensus sites have been identified. Some of these factors have extensive homologies with Sp1 and thus belong to the Sp1 transcription factor family, such as Sp2, Sp3 and DeltaSp3(16) , whereas others are entirely different from Sp1, such as ETF and GC-box binding protein (GCF)(27, 28) . Notably, Sp3 and GC-box binding protein have been shown to bind to the GC-boxes, including Sp1 consensus sites, and repress transcription from certain genes(27, 29) . More experiments are needed to determine if Sp1, its family members, or other novel GC-box binding proteins are involved in the regulation of p15 and p21 genes by TGF-beta. It is possible that the subtle sequence variations and the optimal spacing between binding sites for various transcription factors could alter the balance between the positive and negative transcription regulators and consequently exert a different mode of transcription regulation.


FOOTNOTES

*
This research was supported in part by National Institutes of Health Grant DK45746 and Council for Tobacco Research Grant 3613 (to X.-F. W.) and by National Institutes of Health Grant CA 65572 (to Y. X.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Supported by a grant from the Lucille P. Markey Foundation to the Program in Molecular Biology and Biotechnology.

Pew Scholar and American Cancer Society Junior Faculty member.

**
Leukemia Society Scholar. To whom correspondence should be addressed. Tel.: 919-681-4861; Fax: 919-681-7152.

(^1)
The abbreviations used are: TGF-beta, transforming growth factor beta; CDK, cyclin-dependent kinase; bp, base pair(s); TBP, TATA box-binding protein; RLU, relative light unit; TAF, TBP-associated factor.


ACKNOWLEDGEMENTS

We thank C. Bassing, M. Datto, P. Hu, and H. Symonds for helpful discussion of the manuscript and Y. Yu for technical assistance.


REFERENCES

  1. Massague, J. (1990) Annu. Rev. Cell Biol. 6, 597-641 [CrossRef]
  2. Lyons, R. M., and Moses, H. L. (1990) Eur. J. Biochem. 187, 467-473 [Abstract]
  3. Roberts, A. M., and Sporn, M. B. (1990) in Peptide Growth Factors and Their Receptors (Sporn, M. B., and Boberts, A. B., eds) Part 1, pp. 421-427, Springer-Verlag, Berlin
  4. Laiho, M., Decaprio, J. A., Ludlow, J. W., Livingston, D. M., and Massague, J. (1990) Cell 62, 175-185 [Medline] [Order article via Infotrieve]
  5. Sherr, C. J., and Roberts, J. M. (1995) Genes & Dev. 9, 1149-1163
  6. Nevins, J. R. (1992) Science 258, 424-429 [Medline] [Order article via Infotrieve]
  7. Hannon, G. J., and Beach, D. (1994) Nature 371, 257-261 [CrossRef][Medline] [Order article via Infotrieve]
  8. Datto, M. B., Li, Y., Panus, J. F., Howe, D. J., Xiong, Y., and Wang, X. F. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 5545-5549 [Abstract]
  9. Serrano, M., Hannon, G. J., and Beach, D. (1993) Nature 366, 704-707 [CrossRef][Medline] [Order article via Infotrieve]
  10. Kamb, A., Gruis, N. A., Weaver Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R., Johnson, B. E., and Skolnick, M. H. (1994) Science 264, 436-440 [Medline] [Order article via Infotrieve]
  11. Guan, K. L., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O'Keefe, C. L., Matera, A. G., and Xiong, Y. (1994) Genes & Dev. 8, 2939-2952
  12. Sanger, F., Nicklen, S., and Coulson, A. R. (1992) Bio/Technology 24, 104-108 [Medline] [Order article via Infotrieve]
  13. Kunkel, T. A., Bebenek, K., and McClary, J. (1991) Methods Enzymol. 204, 125-139 [Medline] [Order article via Infotrieve]
  14. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983) Nucleic Acids Res. 11, 1475-1489 [Abstract]
  15. Smale, S. T., and Baltimore, D. (1989) Cell 57, 103-113 [Medline] [Order article via Infotrieve]
  16. Udvadia, A. J., Templeton, D. J., and Horowitz, J. M. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 3953-3957 [Abstract/Free Full Text]
  17. Kadonaga, J. T., Carner, K. R., Masiarz, F. R., and Tjian, R. (1987) Cell 51, 1079-1090 [Medline] [Order article via Infotrieve]
  18. Briggs, M. R., Kadonaga, J. T., Bell, S. P., and Tjian, R. (1986) Science 234, 47-52 [Medline] [Order article via Infotrieve]
  19. Gill, G., Pascal, E., Tseng, Z. H., and Tjian, R. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 192-196 [Abstract]
  20. Kim, S. J., Onwuta, U. S., Lee, Y. I., Li, R., Botchan, M. R., and Robbins, P. D. (1992) Mol. Cell. Biol. 12, 2455-2463 [Abstract]
  21. Udvadia, A. J., Rogers, K. T., Higgins, P. D., Murata, Y., Martin, K. H., Humphrey, P. A., and Horowitz, J. M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 3265-3269 [Abstract]
  22. Geiser, A. G., Busam, K. J., Kim, S. J., Lafyatis, R., O'Reilly, M. A., Webbink, R., Roberts, A. B., and Sporn, M. B. (1993) Gene (Amst.) 129, 223-228 [CrossRef][Medline] [Order article via Infotrieve]
  23. Thut, C. J., Chen, J.-L., Klemm, R., and Tjian, R. (1995) Science 267, 100-104 [Medline] [Order article via Infotrieve]
  24. Verrijzer, C. P., Chen, J.-L., Yokomori, K., and Tjian, R. (1995) Cell 81, 1115-1125 [Medline] [Order article via Infotrieve]
  25. Wang, E. H., and Tjian, R. (1994) Science 263, 811-814 [Medline] [Order article via Infotrieve]
  26. Hisatake, K., Hasegawa, S., Takada, R., Nakatani, Y., Horikoshi, M., and Roeder, R. G. (1993) Nature 362, 179-181 [CrossRef][Medline] [Order article via Infotrieve]
  27. Kageyama, R., and Pastan, I. (1989) Cell 59, 815-825 [Medline] [Order article via Infotrieve]
  28. Kageyama, R., Merlino, G. T., and Pastan, I. (1989) J. Biol. Chem. 264, 15508-15514 [Abstract/Free Full Text]
  29. Hagen, G., Muller, S., Beato, M., and Suske, G. (1994) EMBO J. 13, 3843-3851 [Abstract]
  30. Datto, M. B., and Wang, X.-F. (1995) J. Biol. Chem. 270, in press

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.